This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rebecca Lumley
1 Jul 2022

WuXi STA launches new HPAPI production facility in China

The new plant features flow chemistry and milling technology, as well as reactors up to 3,000 liters

WuXi STA, a subsidiary of WuXi AppTec, continues its investment in manufacturing with the opening of another high-potency API (HPAPI) plant in China. 

The new plant will bolster capacity for high-potency API process R&D and manufacturing services and is located at the company’s Changzhou site in Jiangsu. It features reactors ranging from 250 liters to 3,000 liters, flow chemistry and milling technology, as well as prep-HPLC systems and a 10 m2 tray lyophilizer. 

The company now has two sites—Changzhou and Shanghai—that will help support WuXi STA's development and manufacturing of HPAPIs. Each of the production sites have multiple high potency processes, R&D labs, kilo labs, and other technologies. 

The Changzhou site is capable of handling the process development and manufacturing services for linkers, oligonucleotides, and peptides, providing a ‘one-stop’ solution to companies developing therapies made of various complex conjugate modalities, the company said.  

WuXi STA is a Contract Research, Development and Manufacturing Organisation (CRDMO) that provides solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses. Such uses include the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.   

Rebecca Lumley
Digital Editor - Pharma

Related News